Entry Point Capital, LLC Dyne Therapeutics, Inc. Put Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Put Options
0 transactions
Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
---|
Others Institutions Holding DYN
# of Institutions
201Shares Held
106MCall Options Held
82.7KPut Options Held
24.8K-
Atlas Venture Life Science Advisors, LLC8.02MShares$265 Million37.7% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$259 Million40.83% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$244 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.39MShares$211 Million3.76% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$200 Million3.22% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.71B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...